Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.16% | 0.04% | -5.89% | -8.15% | -9.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.16% | 0.04% | -5.89% | -8.15% | -9.83% |
| Cost of Revenue | -7.59% | -11.14% | 20.51% | 35.38% | 14.33% |
| Gross Profit | 29.40% | 8.16% | -19.70% | -29.90% | -22.63% |
| SG&A Expenses | 37.70% | 6.68% | -12.35% | -21.69% | -14.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.26% | -2.38% | 4.76% | -0.41% | -3.41% |
| Operating Income | -28.10% | 752.53% | -3,891.36% | -130.94% | -71.02% |
| Income Before Tax | -24.61% | 1,858.97% | -788.00% | -226.42% | -102.25% |
| Income Tax Expenses | 164.04% | -141.07% | -56.73% | -48.64% | 106.98% |
| Earnings from Continuing Operations | -27.74% | 172.45% | -72.09% | -82.88% | -102.35% |
| Earnings from Discontinued Operations | -- | 92.21% | 103.01% | -72.40% | 64.23% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.76% | 101.34% | 92.22% | -4,411.36% | -7.95% |
| EBIT | -28.10% | 752.53% | -3,891.36% | -130.94% | -71.02% |
| EBITDA | -51.60% | 47.12% | -3,619.23% | -1,274.60% | -509.05% |
| EPS Basic | -9.65% | 101.37% | 92.03% | -4,584.75% | -10.97% |
| Normalized Basic EPS | -31.70% | 20.94% | -802.17% | -237.11% | -108.00% |
| EPS Diluted | -8.63% | 101.05% | 92.03% | -4,703.39% | -12.02% |
| Normalized Diluted EPS | -31.70% | 18.12% | -802.17% | -234.05% | -108.00% |
| Average Basic Shares Outstanding | -5.36% | -2.08% | -2.36% | -3.20% | -2.73% |
| Average Diluted Shares Outstanding | -5.36% | 0.31% | -2.36% | -2.28% | -2.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |